Dexamethason implant versus posterior sub‐tenon triamcinolone acetonide for treatment of macular edema and/or vitritis in intraocular inflammatory diseases. Retrospective cases‐series

Abstract

AbstractPurpose To demonstrate efficacy and side‐effect of Ozurdex® compared with posterior sub‐tenon triamcinolone acetonide (PSTA) for the treatment of intraocular inflammatory diseases.Methods The medical records of 36 eyes (33 patients) with uveitic or pseudophakic (Irvine‐Gass syndrome) cystoid macular edema and/or vitritis were reviewed. Twenty seven eyes received Ozurdex® and 20 eyes received 40 mg of PSTA. Eleven eyes received PSTA followed by Ozurdex®.Results A beneficial response to treatment with Ozurdex® was seen in all 27 eyes (100%) but was efficient in 16 out of 20 eyes (80%) after PSTA. The best improvement in visual acuity (VA), resolution of vitritis and reduction in central foveal thickness (CFT) was achieved at 4 weeks with Ozurdex® and between 4 weeks to 8 weeks with PSTA. The median time‐before‐recurrence in patients receiving Ozurdex® versus PSTA was 5.7 months and 6.4 months, respectively. In 3 and 8 patients, no reinjection of PSTA and Ozurdex® were respectively performed due to a combined initiation of corticosteroids and/or immunosuppressive treatment. VA improved from baseline by 0.8 and 0.69(P: .506) and CFT decreased from baseline by 188 µm and 148µm with Ozurdex® and PSTA, respectively(P: .516). The results with Ozurdex® were better than those with PSTA, although the difference did not reach statistical significance. An increase in intraocular pressure (>5 mmHg greater than baseline) was observed in 8 eyes (29%) with Ozurdex® and in 2 eyes (10%) with PSTA well controlled with antiglaucoma medications, though.Conclusion In contrast with PSTA, Ozurdex® was associated with clinical improvement in all patients, mainly as supplementary therapy. Commercial interest